newsfilter
← Latest News
PR Newswire·

Atossa Appoints Mark Daniel, CPA, as Chief Financial Officer to Lead Finance, Systems, and Capital Strategy for Commercial Readiness

  • Atossa Therapeutics appointed Mark Daniel, CPA, as Chief Financial Officer on October 14, 2025.
  • Daniel possesses over 25 years of life-science finance experience, including managing budgets exceeding $200M \& delivering over $50M in cost savings.
  • He brings specific expertise in Sarbanes-Oxley (SOX) controls, weekly revenue forecasting, \& treasury management for a $400M cash portfolio.
  • His background includes executing nearly $1B in equity, convertible debt, \& credit transactions across varying market conditions.
  • The appointment supports Atossa's transition from clinical development to commercial operations with (Z)-endoxifen.
  • CEO Steven Quay emphasized the need for revenue-ready systems, disciplined spending, \& milestone-aligned financing.
  • Daniel's role will focus on aligning spending with value-creating milestones \& establishing a balanced financing strategy.
  • Atossa aims to strengthen ERP/CRM/BI systems to unify bookings-to-cash processes \& improve plan-to-actual accuracy.
  • The company maintains a Nasdaq listing (ATOS) \& focuses on innovative breast cancer therapies.
  • The press release includes standard forward-looking statements regarding commercial readiness \& regulatory risks.